Claims
- 1. A racemic or enantiomerically enriched phenylalkyldiamine or amine compounds represented by the following structural formula (I):
- 2. A racemic or enantiomerically enriched phenylalkyldiamine compound represented by the structural formula (I), in accordance with claim 1, wherein m is 1, n is 1, R1 and R2 are hydrogen, Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine or their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 3. A racemic or enantiomerically enriched phenylalkyldiamine compound represented by the structural formula (I), in accordance with claim 1, wherein m is 0, n is 2, R1 and R2 are hydrogen, Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine and their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 4. A racemic or enantiomerically enriched phenylalkylamino amide compounds represented by the following structural formula (XI):
- 5. A racemic or enantiomerically enriched phenylalkylamino amide compounds represented by the structural formula (XI), in accordance with claim 4, wherein m is 1, n is 1, R3 are hydrogen or substituted aromatic ring such as phenyl, 3,4-dichlorophenyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine or their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 6. A racemic or enantiomerically enriched phenylalkylamino amide compounds represented by the structural formula (XI), in accordance with claim 4, wherein m is 0, n is 2, R3 are hydrogen or substituted aromatic ring such as phenyl, 3,4-dichlorophenyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine or their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 7. A racemic or enantiomerically enriched phenylalkylamino amide compounds represented by the following structural formula (XVI):
- 8. A racemic or enantiomerically enriched phenylalkylamino amide compounds represented by the structural formula (XVI), in accordance with claim 7, wherein m is 1, n is 1 and 1 is 0-3; R3 are hydrogen or substituted aromatic ring such as phenyl, 3,4-dichlorophenyl; R4 are lower alkyl such as methyl, ethyl, propyl, butyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine or their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 9. A racemic or enantiomerically enriched phenylalkylamino amide compounds represented by the structural formula (XVI), in accordance with claim 7, wherein m is 0, n is 2 and 1 is 0-3; R3 are hydrogen or substituted aromatic ring such as phenyl, 3,4-dichlorophenyl; R4 are lower alkyl such as methyl, ethyl, propyl, butyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine and their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 10. A racemic or enantiomerically enriched phenylalkylamino sulfonamide compounds represented by the following structural formula (XIV):
- 11. A racemic or enantiomerically enriched phenylalkylamino sulfonamide compounds represented by the structural formula (XIV), in accordance with claim 10, wherein m is 1, n is 1; R5 are methyl or substituted aromatic ring such as phenyl, 2-nitrophenyl, 4-methylphenyl, 2,4-dinitrophenyl, 3-nitrophenyl, 2,4,6-triisopropylphenyl, 2-thiophenyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine and their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 12. A racemic or enantiomerically enriched phenylalkylamino sulfonamide compounds represented by the structural formula (XIV), in accordance with claim 10, wherein m is 0, n is 2; R5 are methyl or substituted aromatic ring such as phenyl, 2-nitrophenyl, 4-methylphenyl, 2,4-dinitrophenyl, 3-nitrophenyl, 2,4,6-triisopropylphenyl, 2-thiophenyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine and their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 13. A racemic or enantiomerically enriched phenylalkyldiamine compounds represented by the following structural formula (XII):
- 14. A racemic or enantiomerically enriched phenylalkyldiamine compounds represented by the structural formula (XII), in accordance with claim 13, wherein m is 1, n is 1 and 1 is 0-3; R3 are hydrogen or substituted aromatic ring such as phenyl, 3,4-dichlorophenyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine and their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 15. A racemic or enantiomerically enriched phenylalkyldiamine compounds represented by the structural formula (XII), in accordance with claim 13, wherein m is 0, n is 2 and 1 is 0-3; R3 are hydrogen or substituted aromatic ring such as phenyl, 3,4-dichlorophenyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine and their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 16. A racemic or enantiomerically enriched phenylalkyldiamine compounds represented by the following structural formula (XVII):
- 17. A racemic or enantiomerically enriched phenylalkyldiamine compounds represented by the structural formula (XVII), in accordance with claim 16, wherein m is 1, n is 1 and 1 is 0-3; R3 are hydrogen or substituted aromatic ring such as phenyl, 3,4-dichlorophenyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine and their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 18. A racemic or enantiomerically enriched phenylalkyldiamine compounds represented by the structural formula (XVII), in accordance with claim 16, wherein m is 0, n is 2 and 1 is 0-3; R3 are hydrogen or substituted aromatic ring such as phenyl, 3,4-dichlorophenyl; Z are 5 to 7-membered aliphatic cyclic compounds including pyrrolidine, piperidine, hexamethyleneimine, morpholine, 4-benzylpiperidine, N-benzylpiperazine, substituted 4-benzoylpiperidine or their derivatives having the general formula (II) or (II′) and the pharmaceutically acceptable salts thereof.
- 19. A phenylalkyldiamine and amide compound represented by the structural formula (I), in accordance with claim 1, selected from the group consisting of
d-1-benzyl-2-(1-hexamethyleneimino) ethylamine dihydrochloride; d-1-benzyl-2-(1-morpholino)ethylamine dihydrochloride; d-1-benzyl-2-(1-pyrrolidinyl)ethylamine dihydrochloride; l-1-benzyl-2-(N-succinimidyl)ethylamine hydrochloride; l-1-benzyl-2-(1-pyrrolidinyl)ethylamine dihydrochloride; d-1-benzyl-2-(1-piperidinyl)ethylamine dihydrochloride; 1-benzyl-2-(1-pyrrolidinyl)ethylamine dihydrochloride; 1-(3,4-dichlorobenzyl)-2-(1-pyrrolidinyl)ethylamine dihydrochloride; 1-(4-chlorobenzyl)-2-(1-pyrrolidinyl)ethylamine dihydrochloride; 1-(3-chlorobenzyl)-2-(1-hexamethyleneimino)ethylamine dihydrochloride; 1-[4-(tert-butyl)benzyl]-2-(1-hexamethyleneimino)ethylamine dihydrochloride; 1-[4-(trifluoromethyl)benzyl]-2-(1-hexamethyleneimino)ethylamine dihydrochloride; 1-(4-chlorobenzyl)-2-(1-hexamethyleneimino)ethylamnine dihydrochloride; 1-(3,4-dichlorobenzyl)-2-(1-hexamethyleneimino)ethylamine dihydrochloride; 1-[3-(trifluoromethyl)benzyl]-2-(1-hexamethyleneimino)ethylamine dihydrochloride; 1-(2,6-dichlorobenzyl)-2-(1-hexamethyleneimino)ethylamine dihydrochloride; 1-(2-methylbenzyl)-2-((-hexamethyleneimino)ethylamnine dihydrochloride; 1-(3-chlorobenzyl)-2-(;-pyrrolidinyl)ethylamine dihydrochloride; 1-[4-(trifluoromethyl)benzyl=-2-(l-pyrrolidinyl)ethylamine dihydrochloride 1-(2,4-dichlorobenzyl)-2-(1-hexamethyleneimino)ethylamnine dihydrochloride; 1-(phenethyl)-2-(1-hexamethyleneimino) ethylamine dihydrochloride; 1-(3,4-dichlorobenzyl)-2-[1-(4-benzylpiperidinyl)]ethylamine dihydrochloride; 1-[4-(tert-butyl)benzyl]-2-2l-(4-benzylpiperidinyl)]ethylamnine dihydrochloride; 1-(2,4-dichlorobenzyl)-2-[1-(4-benzylpiperidinyl)lethylamine dihydrochloride; 1-(4-chlorobenzyl)-2-[1-(4-benzoylpiperidinyl)] ethylamine; 1-[4-(tert-butyl)benzyl]-3-[1-(4-benzoylpiperidinyl)]propylamnine; 1-[4-(tert-butyl)benzyl]-3-[1-(4-(phenylacetyl)]piperidinyl)] propylamine; 1-[4-(tert-butyl)benzyl]-3-[1-(4-benzylpiperidinyl)] propylamine; d-1-benzyl-2-[1-(4-benzoylpiperidinyl)] ethylamine; 1-benzyl-2-[1-(4-benzoylpiperidinyl)] ethylamine; l-1-benzyl-2-[1-(4-benzoylpiperidinyl)] ethylamine; l-1-benzyl-2-[1-4-(phenylacetyl)piperidinyl)] ethylamine; l-1-benzyl-2-[1-4-(4-chlorobenzoyl)piperidinyl)] ethylamine; l-1-benzyl-2-[1-4-(4-fluorobenzoyl)piperidinyl)] ethylamine; l-1-benzyl-2-[1-4-(3,4-dichlorobenzoyl)piperidinyl)] ethylamine; 1-(3,4-dichlorobenzyl)-2-[1-4-benzoylpiperidinyl)] ethylamine; 1-(4-chlorobenzyl)-2-[0-(4-(3,4-dichlorobenzoyl)piperidinyl)] ethylamine; 1-(34-dichlorobenzyl)-2-[1-4-(3,4-dichlorobenzoyl)piperidinyl)] ethylamine; l-(4-(4-methoxybenzoyl)piperidinyl)] ethylamine; 1-(4-chlorobenzyl)-2-[1-4-(4-methoxybenzoyl)piperidinyl)] ethylamine; l-1-benzyl-2-[1-4-(4-tert-butylbenzoyl)piperidinyl)] ethylamine; 1-[4-(tert-butyl)benzyl]-2-[1-4-benzoylpiperidinyl)] ethylamine; 1-phenyl-3-(1-hexamethyleneimino-no)-n-propylamine dihydrochloride; 1-phenyl-2-(1-pyrrolidinyl)ethylamine dihydrochloride; 1-phenyl-3-(1-pyrrolidinyl)-n-propylamine dihydrochloride; 1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine dihydrochloride; 1-phenyl-3-(l-piperidinyl)-n-propylamine; 1-phenyl-4-(1-hexamethyleneimino)-n-butylamine dihydrochloride; 1-phenyl-5-(1-hexamethyleneimino)-n-pentylamine; 1-phenyl-3-[1-(3-methylpiperidinyl)]-n-propylamine; 1-phenyl-3-[1-4-benzoylpiperidinyl)]-n-propylamine dihydrochloride; 1-phenyl-3-[1-1,2,3,4-tetrahydroisoquinolinyl)]-n-propylamnine; 1-phenyl-3-[1-4-(4-fluorobenzoyl)piperidinyl)]-n-propylamine; 1-phenyl-3-[1-4-(phenylacetyl)piperidinyl)]-n-propylamnine; [1-(3-an-no-3-phenyl-propyl)-piperidin-4-yl]-phenyl-methanol; [1-(3-amino-3-phenyl-propyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanol; N-benzoyl-1-(3,4-dichlorobenzyl)-2-(1-hexamethyleneimino) ethylamine; d-N-(2-nitrobenzenesulfonyl)-1-benzyl-2-(l-pyrrolidinyl)ethylamine hydrochloride; N-methyl-N-[2-(3,4-dichlorophenyl)acetyl]-1-[4-(tert-butyl)benzyl]-2-(1-hexamethyleneimnino) ethylamine; N-benzoyl-1-(3,4-dichlorobenzyl)-2-[1-4-benzylpiperidinyl)] ethylamine; N-[2-(3,4-dichlorophenyl)acetyl]-1-(3,4-dichlorobenzyl)-2-[1-4-benzylpiperidinyl)] ethylamine; N-[2-(3,4-Dichlorophenyl)acetyl]-1-(3,4-dichlorobenzyl)-2-(1-hexamethyleneimino) ethylamine; N-benzoyl-1-(2,4-dichlorobenzyl)-2-[1-4-benzylpiperidinyl)] ethylamine; N-[2-(3,4-dichlorophenyl)acetyl]-1-(2,4-dichlorobenzyl]-2-[1-4-benzylpiperidinyl)] ethylamine; N-[2-(3,4-dichlorophenyl)acetyl]-1-phenyl-3-(1-hexamethyleneimino)-n-propylamine; N-(p-toluenesulfonyl)-1-phenyl-3-(1-hexamethyleneimino)-n-propylamine; N-benzoyl-1-phenyl-3-(1-hexamethyleneimino)-n-propylamine; N-[2-(3,4-dichlorophenyl)acetyl]-1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-[2-(3,4-dichlorophenyl)acetyl]-1-phenyl-3-[1-4-(4-fluorobenzoylpiperidinyl))-n-propylamine; N-(p-toluenesulfonyl)-1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-(benzenesulfonyl)-1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-(2,4-dinitrobenzenesulfonyl)-1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-(methanesulfonyl)-1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-(3-nitrobenzenesulfonyl)-1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-(2-nitrobenzenesulfonyl)-i-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-(2,4,6-triisopropylbenzenesulfonyl)-1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-benzoyl-1-phenyl-3-(1-(4-benzylpiperidinyl) ]-n-propylamine; N-(2-thiophenesulfonyl)-1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-(2-nitrobenzenesulfonyl)-1-phenyl-3-[1-4-benzoylpiperidinyl)]-n-propylamine; N-(2-nitrobenzenesulfonyl)-1-phenyl-3-[1-4-(4-fluorobenzoyl)piperidinyl)]-n-propylamnine; N-(2-thiophenesulfonyl)-1-phenyl-3-[1-1,2,3,4-tetrahydroisoquinolinyl)]-n-propylamine; N-benzoyl-1-phenyl-3-[1-(4-benzoylpiperidinyl)]-n-propylamine; N-[2-(3,4-Dichlorophenyl)acetyl]-1-phenyl-3-[1-4-benzoylpiperidinyl)]-n-propylamine; N-benzenesulfonyl-1-phenyl-3-[1-(4-benzoylpiperidinyl)]-n-propylamine; N-acetyl-1-phenyl-3-[1-(4-benzylpiperidinyl)]-n-propylamine; N-benzyl-1-(3,4-dichlorobenzyl)-2-(1-hexamethyleneimino) ethylamine; N-benzyl-1-[4-(tert-butyl)benzyl]-2-(1-hexamethyleneimino) ethylamine; N-benzyl-1-(3,4-dichlorobenzyl)-2-[1-(4-benzylpiperidinyl)] ethylamine; N-(3,4-dichlorophenethyl-1-(3,4-dichlorobenzyl)-2-(1-hexamethyleneimino) ethylamine; N-(3,4-dichlorophenethyl)-1-phenyl-3-(1-hexamethyleneimino)-n-propylamine; N-(3,4-dichlorophenethyl)-1-phenyl-3-[1-4-benzylpiperidinyl)]-n-propylamine; N-formyl-1-(3,4-dichlorobenzyl)-2-(1-hexamethyleneimino) ethylamine; N-formyl-1-(3,4-dichlorobenzyl)-2-[1-(4-benzylpiperidinyl)] ethylamine; N-formyl-1-[4-(tert-butyl)benzyl]-2-[1-(4-benzylpiperidinyl)] ethylamine; N-formyl-1-(2,4-dichlorobenzyl)-2-[1-(4-benzylpiperidinyl)] ethylamine; N-formyl-1-phenyl-3-[1-(4-benzylpiperidinyl)]-n-propylamine; N-(3,4-dichlorophenethyl)-N-formyl-1-phenyl-3-[1-(4-benzylpiperidinyl)]-n-propylamine; N-formyl-N-methyl-1-phenyl-3-[1-(4-benzylpiperidinyl)]-n-propylamine; N-formyl-1-phenyl-3-[1-(4-benzoylpiperidinyl)]-n-propylamine; N-13-[4-(hydroxy-phenyl-methyl)-piperidin-1-yl]-1-phenyl-propyl)-formamide; N-methyl-1-[4-(tert-butyl)benzyl]-2-(1-hexamethyleneimino) ethylamine; N,N-dimethyl-1-[4-(tert-butyl)benzyl]-2-(1-hexamethyleneimino) ethylamine; N-methyl-1-(3,4-dichlorobenzyl)-2-[1-(4-benzylpiperidinyl)] ethylamine; N-methyl-1-[4-(tert-butyl)benzyl]-2-[1-(4-benzylpiperidinyl)] ethylamine dihydrochloride; N-methyl-1-(2,4-dichlorobenzyl)-2-[1-(4-benzylpiperidinyl)] ethylamine; N-methyl-1-phenyl-3-[1-(4-benzylpiperidinyl)]-n-propylamine; N-methyl-1-phenyl-3-(1-hexamethyleneimino)-n-propylamine; N,N-dimethyl-1-phenyl-3-[1-(4-benzylpiperidinyl)]-n-propylamine; and N-methyl-1-phenyl-3-[1-(4-(4-fluorobenzoyl)piperidinyl)]-n-propylamine.
REFERENCE TO RELATED APPLICATION
[0001] This Application claims priority from U.S. Provisional Application 60/297,504 filed Jun. 12, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60297504 |
Jun 2001 |
US |